Mission Therapeutics awarded follow-on therapeutic pipeline programme grant from the Michael J Fox Foundation
Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic Pipeline Programme grant of approximately 0.5M USD from The Michael J Fox Foundation for Parkinson’s Research (MJFF).
Mission Therapeutics participates in the Solebury Trout Fall Private Company Showcase 2021
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that its CEO, Anker Lundemose, will attend and present at the 8th Annual Solebury Trout Private Company Showcase, co-hosted with BMO, on 14 October 2021.
Mission and AbbVie collaboration in Alzheimer’s and Parkinson’s diseases reaches next milestone
Mission Therapeutics, a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration.
Mission Therapeutics takes part in SVB Leerink Biopharma Private Company Connect event
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event.
Mission Therapeutics welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announces the appointment of Jonathan Hepple to the Company’s Board as a Non-Executive Director.
Key appointments strengthen Mission Therapeutics’ senior management team
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced the promotions of Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO with immediate effect.
Mission Therapeutics appoints Dr Bobby Soni to its Board of Directors
Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.
Mission Therapeutics’ highlights positive Parkinson’s Disease USP30 target and inhibitor data
Mission Therapeutics is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.
Mission Therapeutics presents at Michael J Fox Foundation’s Parkinson’s Disease conference
Mission Therapeutics announced that its Medical Director, CNS Translational Medicine, Dr Paul Thompson will be delivering a presentation today at the Parkinson’s Disease Therapeutics Conference in New York City.